Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.
GlobalData on MSN4d
Super Bowl ad for copycat weight loss drugs stokes pharma power debateControversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...
Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
The trial results for amycretin demonstrated a significant weight loss of 24.0% at the 20mg dose over a period of 36 weeks, surpassing investor expectations. However, Novo Nordisk also faces ...
The trial results for amycretin demonstrated a significant weight loss of 24.0% at the 20mg dose over a period of 36 weeks, surpassing investor expectations. However, Novo Nordisk also faces potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback